<DOC>
	<DOCNO>NCT00078039</DOCNO>
	<brief_summary>The primary objective double blind phase study evaluate efficacy safety 3 fix dosage paliperidone ER ( 6 , 9 , 12 mg/day ) compare placebo adult patient schizophrenia .</brief_summary>
	<brief_title>Trial Evaluating Three Fixed Dosages Paliperidone Extended-Release ( ER ) Tablets Olanzapine Treatment Patients With Schizophrenia</brief_title>
	<detailed_description>Paliperidone develop new therapeutic agent treatment schizophrenia . The ER formulation paliperidone develop deliver paliperidone relatively constant rate 24-hour period improve tolerability profile decrease potential orthostatic hypotension . This study design evaluate efficacy safety 3 fix dosage paliperidone ER ( 6 , 9 , 12 mg/day ) compare placebo patient schizophrenia . This trial multicenter , double-blind ( neither patient physician know placebo drug give dose ) , randomize ( patient assign different treatment group base solely chance ) , placebo- active-controlled , parallel-group , dose-response study . The study include screening period 5 day , follow double-blind treatment phase 6 week . Following double-blind treatment phase , eligible patient ( complete 6-week double-blind phase discontinue due lack efficacy minimum 21 day ) may enter 52-week open-label extension phase paliperidone ER monotherapy . Patients randomly assign 1 5 treatment ( paliperidone ER 6 , 9 , 12 mg , olanzapine 10 mg , placebo ) take oral dosage assign treatment daily 6-week double-blind period . At time patient enter double-blind period , must inpatient , must remain hospital minimum 14 full day . While patient hospitalize , efficacy assess twice first week end second week . After patient discharge hospital , return efficacy safety assessment perform weekly basis end 6-week double-blind period . The efficacy response measure change PANSS total score start treatment end double-blind phase . Safety monitor throughout study include assessment incidence adverse event ; measurement extrapyramidal symptom use 3 rating scale ( Abnormal Involuntary Movement Scale [ AIMS ] , Barnes Akathisia Rating Scale [ BARS ] , Simpson-Angus Rating Scale [ SAS ] ) ; measurement vital sign ( lie stand blood pressure , pulse , temperature ) ; electrocardiogram ; clinical laboratory test . Double-blind : 6- , 9- , 12-mg fix dose paliperidone ER , olanzapine 10 mg placebo take orally daily 6 week . Open-label extension : start paliperidone ER 9 mg take orally day ; maintain flexible oral dosage paliperidone ER ( 3 , 6 , 9 , 12 mg/day ) 52 week .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<mesh_term>Olanzapine</mesh_term>
	<criteria>Doubleblind phase : DSMIV diagnosis schizophrenia least 1 year prior screen experience acute episode , total PANSS score screen 70 120 agree voluntary hospitalization minimum 14 day willing able fill selfadministered questionnaire able compliant selfadministration medication , consistent help/support available . Openlabel extension phase : complete 6 week doubleblind treatment complete least 21 day treatment discontinue due lack efficacy patient investigator agree openlabel treatment best interest patient . Doubleblind phase : DSMIV axis I diagnosis schizophrenia DSMIV diagnosis substance dependence within 6 month prior screen evaluation ( nicotine caffeine dependence exclusionary ) history tardive dyskinesia neuroleptic malignant syndrome ( NMS ) history severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) previous history lack response ( 2 adequate trial ) antipsychotic significant risk suicidal violent behavior . Openlabel phase : At significant risk suicidal violent behavior receive injection depot antipsychotic since entry precede doubleblind phase .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>Schizophrenia , paliperidone</keyword>
</DOC>